5ÔÂ24ÈÕ£¬333ÌåÓý¹ÙÍø×ÔÖ÷Ñз¢µÄÖÐÊàÉñ¾ÏµÍ³£¨CNS£©Ö×ÁöϵÁзÖ×Ó¼ì²âÏîÄ¿ÕýʽÉÏÏß¡£¸ÃϵÁвúÆ·»ùÓÚNGS¡¢PCR¡¢¼×»ù»¯Ð¾Æ¬µÈ¶àÊÖÒÕÆ½Ì¨£¬ÎªCNSÖ×ÁöµÄ¸¨ÖúÕï¶Ï¡¢Ô¤ºóÆÀ¹À¡¢¾«×¼ÓÃÒ©µÈÌṩ¸ü¸ß¼ÛÖµµÄ²Î¿¼ÐÅÏ¢£¬Ò»Á¬Öª×ãÁÙ´²Ò½Éú¾«×¼ÕïÁÆÐèÇó¡£
ÖÐÊàÉñ¾ÏµÍ³£¨CNS£©Ö×Áö£¬Éæ¼°Ò»×éÔ´×ÔÄÔÓë¼¹Ëè×éÖ¯µÄÁ¼ÐԺͶñÐÔ¼²²¡£¬¹Å°åÉÏÒÀ¾Ý×éÖ¯²¡ÀíÑ§ÌØÕ÷·ÖÀࡣȻ¶ø£¬Ëæ×ŽüÄêÀ´·Ö×ÓÉúÎïѧµÄÏ£Íû£¬ÌØÊâÊÇзÖ×Ó±ê¼ÇÎïµÄÓ¿ÏÖ£¬CNSÖ×ÁöµÄ·ÖÀàϵͳÒÑÂõÈë·Ö×ÓÕï¶Ï¸¨ÖúµÄʱ´ú£¬Õâ²»µ«¼ÓÉîÁËÎÒÃǶÔÖ×ÁöʵÖʵÄÃ÷È·£¬»¹Ôö½øÁËÔ½·¢¸öÐÔ»¯¡¢¸ßЧµÄÖÎÁÆÕ½ÂÔ£¬ÏÔÖøÔöÇ¿ÁË»¼ÕßµÄÖÎÁÆÐ§¹ûºÍÉúÑÄÖÊÁ¿¡£
2016Ä꣬ÌìÏÂÎÀÉú×éÖ¯£¨WHO£©ÒýÈë·Ö×Ó·ÖÐͱê×¼£¬ÎªCNSÖ×ÁöµÄ·ÖÀàϵͳ¼ÓÈëÁË·Ö×Ó²ãÃæµÄ¿¼Á¿¡£2021Ä꣬WHOÐû²¼µÄCNSÖ×Áö·ÖÀàµÚÎå°æÖУ¬½øÒ»²½½«·Ö×ÓÕï¶Ï¡¢×éÖ¯ÐÎ̬ѧ¼°ÃâÒß×黯ÆÊÎöÏàÍŽᣬ×é³ÉÁËCNSÖ×Áö¾«×¼Ò½ÁƵÄлùʯ¡£ ΪÁ˽øÒ»²½Öª×ãÁÙ´²¾«×¼ÕïÁÆÐèÇó£¬ÌáÉýCNSÖ×ÁöÕï¶Ïˮƽ£¬333ÌåÓý¹ÙÍøÐÂÍÆ³öÁËһϵÁÐCNSÖ×Áö¼ì²âÏîÄ¿¡£
ÖÐÊàÉñ¾ÏµÍ³Ö×Áö»ùÒò¼ì²â-NGSƽ̨
»ùÓÚ¶àÖØPCRµÄNGSÊÖÒÕ£¬¸Ã²úÆ·¿ÉÒ»´ÎÐÔ¼ì²âÓëÄÔÖ×ÁöÏà¹ØµÄ¶àÖÖ±äÒìÐÅÏ¢£¨°üÀ¨SNV/InDel/CNV/LOH/Fusion£©£¬º¸Ç¸ßÖ¤¾ÝÆ·¼¶µÄÒ©Îï°Ðµã£¬ÎªÄÔÖ×Áö¸¨ÖúÕï¶Ï¡¢Ô¤ºóÆÀ¹À¡¢¾«×¼ÓÃÒ©Ìṩ²Î¿¼ÐÅÏ¢£¬¸¨ÖúÁÙ´²Öƶ©¸öÌ廯ÕïÁƼƻ®¡£

ÖÐÊàÉñ¾ÏµÍ³Ö×Áö»ùÒò¼ì²â-PCRƽ̨ ÄÔ½ºÖÊÁöMGMT¼×»ù»¯¼ì²â£º×¨ÃÅÕë¶ÔÄÔ½ºÖÊÁö»¼ÕßµÄMGMTÆô¶¯×ÓÇøÓòµÄ¼×»ù»¯×´Ì¬¾ÙÐмì²â¡£¸Ã²úÆ·»ùÓÚÓ«¹âPCRÒªÁ죬¼´Í¨¹ýÌØÒìÐÔÓ«¹â̽Õë¼ì²âMGMT¼×»ù»¯ÈÈÃÅÇøÓòµÄ7¸öCpGλµãÀ´ÆÊÎöMGMTÆô¶¯×Ó¼×»ù»¯ÇéÐΣ¬Õ¹ÍûÄÔ½ºÖÊÁö»¼Õß¶ÔÌæÄªßò°·µÈÒ©ÎïÁÆÐ§ºÍÔ¤ºó¡£ ÖÐÊàÉñ¾ÏµÍ³Ö×Áö»ùÒò¼ì²â-¼×»ù»¯Ð¾Æ¬
ÄÔÖ×Áö¼×»ù»¯·ÖÐͼì²â£º×¨ÃÅÕë¶ÔÄÔÖ×Áö·ÖÀàµÄÅбðÕï¶ÏºÍ·Ö×ÓÑÇÐÍÆÊÎö£¬ÓÈÆäÊÇÒÉÄÑÕï¶ÏµÄÄÔÖ×Áö»¼Õß¡£¸Ã²úÆ·ÊÇ»ùÓÚ935kоƬ¶ÔÈËÈ«»ùÒò×éÔ¼935,000¸öCpGλµãµÄ¼×»ù»¯×´Ì¬¾ÙÐмì²â£¬ÊµÏÖÄÔÖ×Áö¾«×¼µÄ·Ö×ÓÑÇÐÍ£¬¸¨Öú²¡ÀíÕï¶Ï¡£
³ýÉÏÊöÐÂÉÏÏßÏîĿ֮Í⣬333ÌåÓý¹ÙÍøÒÑÉÏÏßµÄÄÔ½ºÖÊÁö¼ì²âÏîÄ¿£¬»¹°üÀ¨È¾É«Ìå1p/19qÔÓºÏÐÔȱʧ¡¢IDH1/2Í»±ä¼ì²â¡¢TERT»ùÒòÆô¶¯×ÓÍ»±ä¼ì²â¡¢BRAF V600EÍ»±ä¼ì²âµÈ£¬½¨ÉèÁËÒ»Ì×ÍêÕûµÄÄÔÖ×Áö·Ö×ÓÕï¶Ï½â¾ö¼Æ»®¡£
333ÌåÓý¹ÙÍøÆð¾¢¿ªÕ¹ÓëÄÔÖ×ÁöÏà¹Ø¿ÆÑÐÏîÄ¿£¬´ËǰÒѼÓÈëÓɸ´µ©´óѧÁ¥ÊôÎ÷ÔÀÒ½ÔºÖ÷µ¼µÄ¿Æ¼¼²¿2023Äê¶È¡°½Ò°ñ¹Ò˧¡±ÖصãÏîÄ¿¡ª¡ª¡°ÄÔ½ºÖÊÁö×ÛºÏÕïÁÆÐÂÊÖÒÕ¿ª·¢Óëת»¯Ó¦ÓÃÑо¿¡±ÏîÄ¿£¬×¨×¢ÓÚÒºÌå»î¼ì±ê¼ÇÎïÒªº¦Ñз¢»·½Ú£¬¼ÓËÙ¿ÆÑÐÖÁÁÙ´²×ª»¯¡£
333ÌåÓý¹ÙÍøÊǹú¼ÒÊ×ÅúÖ×ÁöÕï¶ÏÓëÖÎÁÆÏîÄ¿¸ßͨÁ¿»ùÒò²âÐòÊÖÒÕÁÙ´²Ó¦ÓÃÊԵ㵥λ¡¢Ê×Åú»ùÒò¼ì²âÊÖÒÕÓ¦ÓÃÊ÷Ä£ÖÐÐÄ¡£×ܲ¿ÊµÑéÊÒÒÑ»ñµÃCAP¹ú¼ÊȨÍþÈÏÖ¤£¬ÑÏ¿áÆ¾Ö¤ISO 15189ÈϿɺÍÃÀ¹úCAPÈÏÖ¤ÒªÇó¾ÙÐÐʵÑéÊÒ±ê×¼ºÍ¹æ·¶µÄ¹ÜÀí£¬Æð¾¢¼ÓÈë²¢¸ßˮƽͨ¹ýº£ÄÚÍâ¶àÏî¸ßͨÁ¿²âÐòÄÜÁ¦ÆÀ¹À¡£ Ëæ×Åмì²âÏîÄ¿µÄÉÏÏߣ¬333ÌåÓý¹ÙÍø½«¼ÌÐøÑÏ¿á°Ñ¿Ø¸÷¸ö¼ì²â»·½Ú£¬ÖúÁ¦ÓÚ¸ßЧºÍ¸öÐÔ»¯ÕïÖμƻ®µÄÑ¡Ôñ£¬Îª¾«×¼Ò½ÁƵÄÁÙ´²Ó¦ÓÃТ˳Á¦Á¿£¬ÎªÊµÏÖ¡°ÈùúÈËÒ»ÂɵطÖÏí¿µ½¡¡±µÄʹÃü¶ø²»Ð¸Æð¾¢¡£ ²Î¿¼ÎÄÏ× [1] Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, Nishikawa R, Rosenthal M, Wen PY, Stupp R, Reifenberger G. Glioma. Nat Rev Dis Primers. 2015 Jul 16;1:15017. doi: 10.1038/nrdp.2015.17. PMID: 27188790. [2] Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106. PMID: 34185076; PMCID: PMC8328013. [3] ÄÔ½ºÖÊÁöÕïÁÆÖ¸ÄÏ£¨2022Äê°æ£©